Literature DB >> 15451145

Inflammation and restenosis after percutaneous coronary interventions.

Konstantinos Toutouzas1, Antonio Colombo, Christodoulos Stefanadis.   

Abstract

The role of inflammation in the development of restenosis after percutaneous coronary interventions has been investigated in several studies. There is an interaction of inflammatory activation and vascular wall response to injury leading to intimal hyperplasia. Percutaneous interventions trigger inflammatory reactions leading to the development of intimal hyperplasia. This reaction is even more prominent in atheromatic plaques in which inflammatory cells have already been activated. In the clinical setting there are several methods for the recognition of the inflammatory activation. In this article we review the data for the role of inflammatory process in restenosis and the significance of identifying the inflamed lesions prior to the intervention. Moreover, the therapeutic implications for the inhibition of inflammatory activation are mentioned.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15451145     DOI: 10.1016/j.ehj.2004.06.011

Source DB:  PubMed          Journal:  Eur Heart J        ISSN: 0195-668X            Impact factor:   29.983


  37 in total

1.  Genetic risk factors for restenosis after percutaneous coronary intervention in Kazakh population.

Authors:  Elena V Zholdybayeva; Yerkebulan A Talzhanov; Akbota M Aitkulova; Pavel V Tarlykov; Gulmira N Kulmambetova; Aisha N Iskakova; Aliya U Dzholdasbekova; Olga A Visternichan; Dana Zh Taizhanova; Yerlan M Ramanculov
Journal:  Hum Genomics       Date:  2016-06-08       Impact factor: 4.639

2.  Inflammatory events in a vascular remodeling model induced by surgical injury to the rat carotid artery.

Authors:  Barbara Rinaldi; Paolo Romagnoli; Stefano Bacci; Rosa Carnuccio; Maria Chiara Maiuri; Maria Donniacuo; Annalisa Capuano; Francesco Rossi; Amelia Filippelli
Journal:  Br J Pharmacol       Date:  2006-01       Impact factor: 8.739

Review 3.  The effects of novel, bioresorbable scaffolds on coronary vascular pathophysiology.

Authors:  Michael J Lipinski; Ricardo O Escarcega; Thibault Lhermusier; Ron Waksman
Journal:  J Cardiovasc Transl Res       Date:  2014-05-07       Impact factor: 4.132

4.  Sam68 impedes the recovery of arterial injury by augmenting inflammatory response.

Authors:  Shuling Han; Shiyue Xu; Junlan Zhou; Aijun Qiao; Chan Boriboun; Wenxia Ma; Huadong Li; Dauren Biyashev; Liu Yang; Eric Zhang; Qinghua Liu; Shayi Jiang; Ting C Zhao; Prasanna Krishnamurthy; Chunxiang Zhang; Stéphane Richard; Hongyu Qiu; Jianyi Zhang; Gangjian Qin
Journal:  J Mol Cell Cardiol       Date:  2019-10-19       Impact factor: 5.000

5.  Liposomal simvastatin attenuates neointimal hyperplasia in rats.

Authors:  Eyal Afergan; Meital Ben David; Hila Epstein; Nickolay Koroukhov; Dalia Gilhar; Keren Rohekar; Haim D Danenberg; Gershon Golomb
Journal:  AAPS J       Date:  2010-02-09       Impact factor: 4.009

6.  Serum profiles of monocyte chemoattractant protein-1 as a biomarker for patients recovering from myocardial infarction.

Authors:  Katarzyna Korybalska; Małgorzata Pyda; Stefan Grajek; Magdalena Lanocha; Andrzej Breborowicz; Janusz Witowski
Journal:  Clin Res Cardiol       Date:  2010-02-07       Impact factor: 5.460

7.  Synthetic peptide fragment (65-76) of monocyte chemotactic protein-1 (MCP-1) inhibits MCP-1 binding to heparin and possesses anti-inflammatory activity in stable angina patients after coronary stenting.

Authors:  T I Arefieva; T L Krasnikova; A V Potekhina; N U Ruleva; P I Nikitin; T I Ksenevich; B G Gorshkov; M V Sidorova; Zh D Bespalova; N B Kukhtina; S I Provatorov; E A Noeva; E I Chazov
Journal:  Inflamm Res       Date:  2011-07-10       Impact factor: 4.575

8.  In vivo evaluation of a novel dexamethasone-heparin-double-coated stent for inhibition of artery restenosis and thrombosis.

Authors:  Qing-Kui Guo; Zhi-Qian Lu; Jin-Ye Wang; Tao Li
Journal:  J Mater Sci Mater Med       Date:  2011-05-10       Impact factor: 3.896

9.  Targeted anti-inflammatory systemic therapy for restenosis: the Biorest Liposomal Alendronate with Stenting sTudy (BLAST)-a double blind, randomized clinical trial.

Authors:  Shmuel Banai; Ariel Finkelstein; Yaron Almagor; Abid Assali; Yonathan Hasin; Uri Rosenschein; Patricia Apruzzese; Alexandra J Lansky; Teruyoshi Kume; Elazer R Edelman
Journal:  Am Heart J       Date:  2012-12-11       Impact factor: 4.749

10.  In vitro photodynamic therapy with chlorin e6 leads to apoptosis of human vascular smooth muscle cells.

Authors:  Magdalena Wawrzyńska; Wojciech Kałas; Dariusz Biały; Ewa Zioło; Jacek Arkowski; Walentyna Mazurek; Leon Strzadała
Journal:  Arch Immunol Ther Exp (Warsz)       Date:  2010-02       Impact factor: 4.291

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.